Arecor Therapeutics focused on Phase 1 trial of diabetes treatment AT278
A key focus for the second half of 2021 is the Phase I clinical trial for AT278 which, if successful, would add significantly to Arecor's diabetes franchise
Company
Arecor Therapeutics PLC
LON:AREC
Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK.
124 stories · page 7 of 7
Arecor Therapeutics appoints Lindsey Foulkes as chief operating officer
Dr Lindsey Foulkes has joined the executive team at Arecor.
Arecor Therapeutics expands reformulation work with Par
"This growing partnership supports both companies' product development strategies to bring enhanced products to market that simplify care and improve patient outcomes," said CEO Sarah Howell
Arecor Therapeutics hails admission of shares to trading on AIM
At the IPO issue price the company has a market capitalisation of roughly £62.5mln